Grand Angels
VC Fund
Holland, United States
Grand Angels is a VC fund in Holland focused on Biotechnology and Software. Grand Angels provides financial consultancy services.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Grand Angels invests in
BiotechnologySoftwareHealth CareAnalyticsManufacturing
Stages Grand Angels invests in
SeedSeries ASeries BFunding RoundConvertible Note
Countries Grand Angels invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Damato Paul
|
|||
Paul Damato
|
|||
Timothy Parker
|
|||
Investment Focus
Industry
- Biotechnology 8 (44%)
- Software 4 (22%)
- Health Care 4 (22%)
- Analytics 3 (17%)
- Manufacturing 3 (17%)
Stage
- Seed 7 (39%)
- Series A 4 (22%)
- Series B 2 (11%)
- Funding Round 2 (11%)
- Convertible Note 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Damato Paul
Managing Director
|
Managing Director | Total investments: 7 | Find email | |
|
Paul Damato
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
|
Timothy Parker
President
|
President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Akadeum Life Sciences
|
Akadeum Life Sciences is working on the problem of isolating mammalian and bacterial cells from complex mixtures. It creates the simplest bioseparation products and fundamentally change the way that isolating cells and other biological targets approached. The company currently uses microbubbles for applications in cell separation and other relatedareas.Akadeum Life Sciences was founded in 2014 and is headquartered in Ann Arbor, Michigan, United States. | $17.5M / Series B / Oct 12, 2021 | |
ONL Therapeutics
|
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $46.9M / Series B / Dec 22, 2020 | |
Ripple Science
|
Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. | Seed / Sep 29, 2020 | |
KitoTech Medical
|
KitoTech Medical is a medical device company developing and commercializing products for wound closure and wound care. It has developed and introduced a revolutionary proprietary wound closure product, microMend, onto the market. It incorporates tiny Microstaples on an adhesive backing, which is the size and shape of a butterfly bandage. microMendis painless and as easy to apply as a bandage. The Microstaples provide the holding strength of sutures resulting in secure anchoring of the device to the skin. These features make microMend ideal for closing surgical incisions and lacerations currently closed with sutures and staples. Clinical studies have demonstrated its superiority over sutures in terms of clinical outcomes, including cosmetic results. It is much faster than sutures and can be applied by less costly medical personnel (nurses, PAs, and nursing assistants) translating into significant cost savings in wound closure procedures. microMend is being marketed in a broad range of surgical specialties as well as dermatology and emergency medicine. The military represents an additional major market for microMend, where the product is also being commercialized. Its potential market is over $600M and $2B in the US and worldwide, respectively. KitoTech Medical was founded in 2011 and is based in Seattle, Washington. | $3M / Convertible Note / Aug 01, 2020 | |
Opus Genetics(formerly Ocuphire Pharma)
|
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night visiondisturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization.The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. | $5M / Seed / Jul 22, 2019 | |
Ambiq Micro
|
Ambiq Micro is an early-stage fabless semiconductor company that is developing ultra-low-power mixed-signal solutions for a new generation of wireless electronics.Ambiq Micro was founded in 2010 on the simple yet powerful notion that extremely low-power semiconductors are the key to the future of electronics. Through the use of their pioneeringultra-low-power technology, they help innovative companies around the world develop differentiated solutions that reduce or eliminate the need for batteries, lower overall system power, and maximize industrial design flexibility. | $11.4M / Jun 05, 2018 | |
Change Dynamix
|
Change Dynamix makes security and risk intelligence easier with behavioral analytics. The value Change Dynamix brings to our clients is the ability to elevate their security and threat awareness with our services and solution with faster detection and cost-efficiency. With continuous changes happening across dynamic organizations piecing togetherall the security data from traditional and log-based security technologies is prone to failure. Analytics on poor data leads to poor results. While other security and risk analytics companies rely on traditional data and SIEM requirements Change Dynamix allows for a change in the approach with better visibility and outcomes for our clients. | $2.1M / Seed / Oct 01, 2017 | |
Tetra Therapeutics
|
Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders. | $5M / Series A / Nov 29, 2016 | |
Tetra Discovery
|
Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system.Their research focuses on developing new treatments for depression and schizophrenia. Severe forms ofdepression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability. | $5M / Series A / Nov 29, 2016 | |
Reconstruct
|
Reconstruct’s a platform provides a ‘virtual command center’ of project replicas that enables project executives to more proactively and precisely manage construction progress including detecting current, past, and future performance issues. The platform’s 3D timelines enable near real-time coordination among general contractors, subs, owners, andlenders.The company was founded in 2016 and is based in Menlo Park, California. | $850K / Seed / Sep 16, 2016 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does Grand Angels invest in?
Grand Angels invests primarily in Biotechnology, Software and Health Care startups, most often at Seed and Series A stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Grand Angels?
Public channels for Grand Angels include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Grand Angels?
The team at Grand Angels includes Damato Paul (Managing Director), Paul Damato (Managing Director) and Timothy Parker (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
